Skip to main content

Year: 2025

BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapiesMultiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech’s pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different countries and regions and maintained global market leadershipFourth quarter and full year 2024 revenues of €1.2 billion and €2.8 billion**, respectivelyFull...

Continue reading

Nexus Industrial REIT Announces Fourth Quarter and Year End 2024 Financial Results

Q4 Net Operating Income grew 10.0% from accretive acquisitions, development, and 5.1% industrial SPNOI Advanced the strategic transition to a pure-play industrial REIT TORONTO, March 10, 2025 (GLOBE NEWSWIRE) — Nexus Industrial REIT (the “REIT”) (TSX: NXR.UN) announced today its results for the fourth quarter and year ended December 31, 2024. “2024 was a formative year for Nexus Industrial, and I am very pleased with the results. We executed a purposeful strategic re-shaping, focusing our business as the Canada-focused pure-play industrial REIT. We made significant future investments, while also delivering strong organic growth”, said Kelly Hanczyk, CEO. “During the year we opportunistically sold our legacy office and non-core industrial properties, and have firm sales contracts for the majority of the retail portfolio, closing...

Continue reading

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial. After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose. When evaluating the...

Continue reading

H World Group Limited Schedules Fourth Quarter and Full Year of 2024 Earnings Release on March 20, 2025

SINGAPORE and SHANGHAI, March 10, 2025 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today announced that it will schedule to release its unaudited financial results for the fourth quarter and full year of 2024 on Thursday, March 20, 2025 (Hong Kong time), after the trading hours of The Stock Exchange of Hong Kong Limited and before the opening of the U.S. market. H World’s management will host a conference call at 8 a.m. (U.S. Eastern time) on Thursday, March 20, 2025 (or 8 p.m. (Hong Kong time) on Thursday, March 20, 2025) following the announcement. To join by phone, all participants must pre-register this conference call using the Participant Registration link of https://register-conf.media-server.com/register/BI303638c962504ffcb81bb09e374f8485....

Continue reading

Synaptics Launches Ultra-Low-Power Wi-Fi/Bluetooth/802.15.4 Triple Combo SoC Family for Embedded Edge AI IoT

SYN461x is optimized for power, system integration, size, and time to market with outstanding rate-over-range and seamless interoperability to target an ~$3.2 billion market opportunity NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Veros™ Triple Combo connectivity portfolio with the SYN461x family of ultra-low-power (ULP) Wi-Fi® 2.4/5/6 GHz, Bluetooth® 6.0 and Bluetooth Low Energy (BLE), and IEEE 802.15.4 (Zigbee®/Thread®) systems on chip (SoCs). Designed for the embedded Edge AI Internet of Things (IoT), the SYN461x is optimized for power, system integration, size, and rapid time to market while delivering Veros’ characteristic outstanding rate-over-range performance and seamless interoperability. The versatile Matter-compliant SoCs offer advanced...

Continue reading

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Five presentations affirm positive outcomes utilizing inhaled insulin An sNDA filing for Afrezza in pediatric population anticipated in 2025DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 10, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. “Data from both the INHALE-1 pediatric and INHALE-3 adult studies continue to drive groundbreaking conversations around inhaled insulin,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area...

Continue reading

Synaptics Extends Edge AI Portfolio with High-Performance Adaptive MCUs for Multimodal Context-Aware Computing

Featuring three power levels, the SR-Series MCUs scale Astra AI-Native hardware and open-source software to accelerate the development of low-power, cognitive IoT devices NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Synaptics AstraTM AI-Native platform with the SR-Series high-performance adaptive microcontroller units (MCUs) for scalable context-aware Edge AI. The series features three tiers of operation: performance (100 GOPS), efficiency, and ultra-low-power (ULP) always-on (AON) to deliver intelligence at every power level. Based on an Arm® Cortex®-M55 core and the Arm Ethos™-U55 neural processing unit (NPU), the SR-Series is supported by the AstraTM Machina Micro development kit and open-source SDK. It is optimized for multimodal consumer,...

Continue reading

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company’s Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Half of 2025 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.,...

Continue reading

Final terms for bonds to be listed 11th March 2025

To Nasdaq Copenhagen A/S                        10th March 2025                                        Announcement no. 22/2025 Final terms for bonds to be listed 11th March 2025 On 11th March 2025, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bonds consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 28th, 2024. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely,Jyske Realkredit A/S www.jyskerealkredit.com Please observe...

Continue reading

With reference to the press release from ÍL Fund and the Ministry of Finance and Economic Affairs concerning the possible winding-up of ÍL Fund

Government Debt Management announces the following change to its annual Prospect for 2025. The current plan is to issue a new inflation-indexed bond series maturing in 2044, with plans for market making. Instead, an inflation-indexed bond maturing in 2050 with planned market making will be issued this year.

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.